PK and PD of PA10040, EC Aspirin and -Omeprazole in healthy volunteers

• Research type

  Research Study

• Full title

  A Phase I, Randomized, Open-Label, 2-Way Cross-Over Study to Evaluate the Pharmacokinetics and Pharmacodynamics (Effect on Intragastric pH) after Seven Daily Oral Doses of PA10040 and EC Aspirin (Bayer Aspirin® Protect) 100 mg plus EC Omeprazole (Losec®) 20 mg in Healthy Subjects

• IRAS ID

  143553

• Contact name

  Annelize Koch

• Contact email

  annelize.koch@parexel.com

• Sponsor organisation

  POZEN Inc.

• Eudract number

  2013-004218-16

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  13/LO/1788

• Date of REC Opinion

  13 Jan 2014

• REC opinion

  Further Information Favourable Opinion